Home Newsfeeds Banc of California Q4 EPS $0.45 Beats $0.43 Estimate

Banc of California Q4 EPS $0.45 Beats $0.43 Estimate

Banc of California (NYSE:BANC) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.43 by 4.65 percent. This is a 95.65 percent increase over earnings of $0.23 per share from the

byBenzinga Newsdesk

January 19, 2023

1 minute read

Cantor Fitzgerald Maintains Neutral on High Tide, Lowers Price Target to C$2.8

By Benzinga Newsdesk

July 25, 5:52 AM

Cantor Fitzgerald analyst Pablo Zuanic maintains High Tide (TSXV:HITI) with a Neutral and lowers the price target from C$4.45 to C$2.8.

TSXV:HITI

Exane BNP Paribas Initiates Coverage On DraftKings with Underperform Rating

By Benzinga Newsdesk

October 6, 8:47 AM

Exane BNP Paribas analyst Alistair Johnson initiates coverage on DraftKings (NASDAQ:DKNG) with a Underperform rating.

DKNG

Monopar Therapeutics Shelves Development Of Validive For Radiation Therapy-Related Complication

By Vandana Singh

March 28, 11:40 AM

Monopar Therapeutics Inc (NASDAQ: MNPR) completed a pre-specified interim analysis for its Validive Phase 2b/3 VOICE trial for the prevention of severe oral mucositis (SOM) in patients undergoing chemoradiotherapy for oropharyngeal cancer (OPC).

MNPR

Nicolet Bankshares Q2 EPS $1.73 Down From $1.77 YoY

By Benzinga Newsdesk

July 19, 4:13 PM

Nicolet Bankshares (NYSE:NIC) reported quarterly earnings of $1.73 per share. This is a 2.26 percent decrease over earnings of $1.77 per share from the same period last year.

NIC

Banc of California Q4 EPS $0.45 Beats $0.43 Estimate

Related Posts

Cantor Fitzgerald Maintains Neutral on High Tide, Lowers Price Target to C$2.8

Exane BNP Paribas Initiates Coverage On DraftKings with Underperform Rating

Monopar Therapeutics Shelves Development Of Validive For Radiation Therapy-Related Complication

Nicolet Bankshares Q2 EPS $1.73 Down From $1.77 YoY